BMS
FHTX icon

Brummer Multi-Strategy’s Foghorn Therapeutics FHTX Stock Holding History

Brummer Multi-Strategy’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,708
Closed -$25.4K – 11
2025
Q4 		$25.4K Buy
+4,708
New +$21.3K 0.15% 11

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Brummer Multi-Strategy's FHTX Position: Q1 2026 in Review

Brummer Multi-Strategy sold out of Foghorn Therapeutics (FHTX) in Q1 2026, closing a stake of 4,708 shares — an estimated $25.4K sold.

Brummer Multi-Strategy first reported a position in FHTX in Q4 2025 and held it in 1 quarter. The position peaked at $25.4K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Brummer Multi-Strategy reported no remaining Foghorn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brummer Multi-Strategy sold 4,708 Foghorn Therapeutics shares in Q1 2026, an estimated $25.4K.
  • Brummer Multi-Strategy first reported a position in Foghorn Therapeutics in Q4 2025 and held it in 1 quarter.
  • Brummer Multi-Strategy's Foghorn Therapeutics position peaked at $25.4K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Brummer Multi-Strategy's 13F filing for Q1 2026, filed 6 May 2026.